Plain-English translation of NCT06326411 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new oral medication called in people with advanced solid cancers that have stopped responding to standard treatments or for whom standard treatments are not suitable. The study has two parts: first, researchers will find the safest and most effective dose, then they will test that dose in larger groups of people with specific types of cancer (like melanoma, lung cancer, and glioma) that have particular genetic mutations. The goal is to see whether this medication can shrink tumors and be tolerated well by patients.
Many advanced cancers have genetic mutations in a pathway called MAPK that drives tumor growth, but current treatment options are limited or stop working over time. This trial exists to find out whether the new treatment can offer a better option for patients with these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take the study medication by mouth once daily in 28-day cycles. The study has two phases: in the first phase, researchers gradually increase doses to find the safest level; in the second phase, larger groups of people with specific cancer types take the recommended dose. Throughout the trial, you will have regular clinic visits for blood tests, imaging scans, and other tests to check how the medication is working and monitor for side effects. Your participation will continue as long as the medication is helping your cancer and you are tolerating it well.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States